I first wrote about Biohaven Pharmaceutical (BHVN) in May 2020, just 3 months after the launch of its first product Nurtec ODT. I was bullish on the company’s prospects, and since that time, Biohaven has seen substantial share price appreciation although it has fallen back a bit of late. Figure […]